ArticleEuropean urology2025
Defining the Histopathological, Clinical, and Genetic Characteristics of Familial BAP1-associated Renal Cell Carcinoma.
Abstract readLetter
In one paragraph
Article in European urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of Homologous Recombination Deficiency (HRD) in Renal Cell Carcinoma (RCC): Biology, Biomarkers, and Therapeutic Opportunities.Current oncology (Toronto, Ont.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
33 authors.
Lina Posada CalderonUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, New York Presbyterian-Weill Cornell Medicine, New York, NY, USA.
Mark T DawidekUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cerise TangComputational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Minsoo KimComputational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Grace ZongDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Chai BandlamudiDepartment of Pathology and Laboratory Medicine, Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Miika MehineDepartment of Pathology and Laboratory Medicine, Marie-Josee and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rania SheikhDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yelena KemelSloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lennert EismannUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, University Hospital Munich, Ludwig Maximilian University of Munich, Munich, Germany.
Marc GanzUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
Daniel BarbakoffUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Lindsey ByrneDivision of Human Genetics, Department of Internal Medicine and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
Isabella GrayDivision of Human Genetics, Department of Internal Medicine and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA.
Daniel NethalaUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Nityam RathiUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Cathy D VockeUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Ying L LiuDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Department of Medicine, Weill Cornell Medical Center, New York, NY, USA.
Alicia LathamDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Zsofia K StadlerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Kenneth OffitDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Jonathan A ColemanUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alvin C GohUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Paul RussoUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ed ReznikComputational Oncology Service, Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert J MotzerDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ying-Bei ChenDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
W Marston LinehanUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Victor E ReuterDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Mohammed H Abdel-RahmanDivision of Human Genetics, Department of Internal Medicine and Comprehensive Cancer Center, Ohio State University, Columbus, OH, USA; Department of Ophthalmology and Visual Science, Ohio State University, Columbus, OH, USA.
Mark W BallUrologic Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
A Ari HakimiUrology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Maria I CarloDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: carlom@mskcc.org.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4MSpectrum of clinical phenotype of the BAP1-tumor predisposition syndrome (BAP1-TPDS)R01CA255323 · NCI · OHIO STATE UNIVERSITY · PI ABDEL-RAHMAN, MOHAMED H. · 2021 to 2025
$2.9MInvestigating the Role of KEAP1 Germline and Somatic Mutations in Renal Cell CarcinomaK08CA272960 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Maria Carlo · 2023 to 2026
$1.1MNCI NIH HHS K08 CA272960NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA255323
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.